BRAF and thyroid cancer: MEK inhibitors, such as trametinib, cobimetinib, or binimetinib, are medications that have been investigated in the treatment of thyroid cancer, often combined with BRAF inhibitors as they block key points in the MAPK signaling pathway; this combination can improve efficacy and reduce treatment resistance 93.